Terminated PHASE2 INTERVENTIONAL 3-arm NCT01261403

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

A Phase 2, Randomized, Double- Blind, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Active Rheumatoid Arthritis

Sponsor: Celgene Corporation

Conditions Rheumatoid Arthritis

Interventions PDA001 Vehicle Controlled Placebo

Updated 9 times since 2017 Last updated: Jul 20, 2020 Started: Dec 31, 2010 Primary completion: Feb 29, 2012 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Enrollment terminated pending additional Phase 1 data

Other terminated trials from Celgene Corporation

More terminations from Celgene Corporation

Other Rheumatoid Arthritis trials with similar outcome

Browse all Rheumatoid Arthritis trials

Listed as NCT01261403, this PHASE2 trial focuses on Rheumatoid Arthritis and remains terminated or withdrawn. Sponsored by Celgene Corporation, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE2
Aug 2020 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Jun 2018 — Aug 2020 [monthly]

Terminated PHASE2
Mar 2018 — Jun 2018 [monthly]

Terminated PHASE2
Feb 2017 — Mar 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Celularity Incorporated

Data source: Celularity Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States , Arcadia, United States , Coral Gables, United States , Dallas, United States , Duncansville, United States , Eagan, United States , Lakewood, United States , Los Angeles, United States , Mayfield, United States , Monroe, United States and 5 more locations